Stayble Therapeutics AB (OSTO:STABL) COGS-to-Revenue : 0.00 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Stayble Therapeutics AB COGS-to-Revenue?

Stayble Therapeutics AB's Cost of Goods Sold for the three months ended in Sep. 2023 was kr0.00 Mil. Its Revenue for the three months ended in Sep. 2023 was kr0.00 Mil.

Stayble Therapeutics AB's COGS to Revenue for the three months ended in Sep. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Stayble Therapeutics AB's Gross Margin % for the three months ended in Sep. 2023 was N/A%.

Stayble Therapeutics AB COGS-to-Revenue Historical Data

The historical data trend for Stayble Therapeutics AB's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB COGS-to-Revenue Chart

Stayble Therapeutics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

Stayble Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Stayble Therapeutics AB COGS-to-Revenue Calculation

Stayble Therapeutics AB's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Stayble Therapeutics AB's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Stayble Therapeutics AB (OSTO:STABL) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Stayble Therapeutics AB's Gross Margin % for the three months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Stayble Therapeutics AB COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Stayble Therapeutics AB (OSTO:STABL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (OSTO:STABL) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

4K4:Germany

Address

Medicinaregatan 8a, Gothenburg, SWE, SE-413 90

Website

http://www.staybletherapeutics.com

Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (OSTO:STABL) Headlines

No Headlines